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SUMMARY
The objective of the current study was to determine if night-shift workers
carrying the five-repeat variant of the Period 3 gene show elevated levels
of nocturnal sleepiness and earlier circadian phase compared with
homozygotes for the four-repeat allele. Twenty-four permanent night-shift
workers were randomly selected from a larger study. Participants took
part in an observational laboratory protocol including an overnight
multiple sleep latency test and half-hourly saliva collection for calculation
of dim-light melatonin onset. Period 3–/5 shift workers had significantly
lower multiple sleep latency test during overnight work hours compared
with Period 34/4 workers (3.52  23.44 min versus 10.39  6.41 min,
P = 0.003). We observed no significant difference in sleepiness during
early morning hours following acute sleep deprivation. Long-allele
carriers indicated significantly higher sleepiness on the Epworth Sleep-
iness Scale administered at 17:00 hours (12.08  2.55 versus
8.00  1.94, P < 0.001). We observed a significantly earlier melatonin
onset in Period 3–/5 individuals compared with Period 34/4 shift workers
(20:44  6:37 versus 02:46  4:58, P = 0.021). Regression analysis
suggests that Period 3 genotype independently predicts sleepiness even
after controlling for variations in circadian phase, but we were unable to
link Period 3 to circadian phase when controlling for sleepiness. Period
3–/5 shift workers showed both subjective and objective sleepiness in the
pathological range, while their Period 34/4 counterparts showed sleep-
iness within normal limits. Period 3–/5 night workers also show a mean
circadian phase 6 h earlier (i.e. less adapted) than Period 34/4 workers.
Because Period 3–/5 workers have maladaptive circadian phase as well
as pathological levels of sleepiness, they may be at greater risk for
occupational and automotive accidents. We interpret these findings as a
call for future research on the role of Period 3 in sleepiness and circadian
phase, especially as they relate to night work.
INTRODUCTION
A variable number tandem repeat (VNTR) polymorphism of
the Period 3 (PER3) gene has been associated with
individual differences in several sleep and circadian functions
(Dijk and Archer, 2010; Goel et al., 2009; Groeger et al.,
2008; Rupp et al., 2013; Viola et al., 2007). Carriers of the
less common five-repeat allele (PER34/5 or PER35/5; here-
after noted PER3–/5) make up about 35–40% of the popu-
lation (Ciarleglio et al., 2008), and PER35/5 individuals are
more susceptible to cognitive decrements following sleep
deprivation, particularly at the circadian nadir (~05:00 hours;
Viola et al., 2007). A recent study comparing PER3 geno-
types showed that PER35/5 individuals had higher indicators
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of sleepiness, such as impaired sustained attention and slow
rolling eye movements, particularly in the early morning hours
during total sleep deprivation (Maire et al., 2014). Similarly,
under severe sleep restriction to 3 h of allotted time in bed for
seven nights, PER34/5 individuals showed greater impair-
ments in daytime neurobehavioural performance compared
with PER34/4 individuals (Rupp et al., 2013), but these
differences did not manifest until the third day of sleep
restriction. In addition, while nocturnal assessments were not
performed, deficits were most prominent in the morning hours
(~08:00 hours). In contrast, a study of more modest sleep
restriction to 4 h per night for five nights did not show an
effect of genotype on performance or alertness (i.e. mainte-
nance of wakefulness test; Goel et al., 2009). Finally, a study
investigating the cognitive effects of both partial and acute
sleep deprivation showed an effect of PER3 genotype on
subjective sleepiness and sustained attention with effects
most pronounced in the early morning hours (Lo et al., 2012).
Taken together, these findings suggest the functional deficits
associated with the PER3 genotype may occur following
situations that include extensive sleep deprivation and/or
involve performing at an adverse circadian phase.
One common situation that involves both restricted sleep
for an extensive period of time in conjunction with require-
ments for maintaining alertness and performance at the
circadian nadir is night-shift work (Drake, 2011). Night
workers often obtain less sleep than their day work
counterparts, and their work schedules inherently require
them to maintain alertness throughout the night. In addition,
research has shown that the early morning hours (01:00–
09:00 hours), which typically include the commute home
from night work, are a particularly vulnerable time for shift
workers due to the elevated risk of automotive and industrial
accidents (Wagstaff and Sigstad Lie, 2011). Given that shift
workers ubiquitously experience sleep restriction and expo-
sure to wakefulness at an adverse circadian phase, workers
who carry the PER3 five-repeat allele may experience
particularly elevated levels of sleepiness during the night-
shift and may correspondingly be at greater risk for
automotive or occupational accidents.
In addition to the possibility that PER3 genotype may
impact nocturnal alertness in night-shift workers, previous
studies demonstrating an association of this polymorphism
with chronotype (Archer et al., 2003) and circadian phase
(Viola et al., 2012) suggest these genotype differences may
also influence circadian adjustment to night work. Numerous
studies have shown that certain individuals adjust better to
night work than others (Drake et al., 2004; Gumenyuk et al.,
2012, 2014; Juda et al., 2013; Reinberg et al., 1978). In a
review of six studies, Folkard concluded that few night
workers experience full adjustment of their circadian rhythms
to night work (Folkard, 2008). In particular, late chronotypes
(‘eveningness/owls’) show better adjustment to night work
(Ostberg, 1973). Considering the finding that homozygotes
for the four-repeat allele are more likely to have a later
chronotype (Archer et al., 2003), this suggests the possibility
that such individuals may have better circadian adjustment to
a night work schedule.
In a recent study, PER3 mediated the efficacy of behavio-
ural adaptation strategies for shift work (Gamble et al., 2011).
These authors found significant genotype–strategy interac-
tions, suggesting that PER3–/5 nurses adapt better to shift
work when they employ certain strategies (i.e. sleep depri-
vation following the final night-shift in a series), relative to
other genotypes. However, circadian phase was not
assessed in that study and no objective measures of
sleepiness were obtained.
Our study differs from this and other protocols by objec-
tively assessing circadian phase and sleepiness in night-shift
workers genotyped for the PER3 VNTR. Our study was
designed to test the hypothesis that night-shift workers who
are carriers of the five-repeat allele may have elevated levels
of nocturnal sleepiness and unadjusted circadian phase
consistent with a lack of adaptation to the sleep–wake
schedule imposed by night work.
MATERIALS AND METHODS
Night workers were recruited from healthcare and industrial
settings to participate in an overnight laboratory study.
Participants were required to have worked exclusively on a
night-shift for at least 6 months (at least three night-shifts per
week, with each shift lasting 8 h or longer, and occurring
between 19:00 and 08:00 hours) and must not have worked
a rotating shift or ‘picked up’ daytime shifts during the
6 months preceding the laboratory study. Only individuals
who were continuing to be on the night-shift without any
anticipated work schedule changes participated. They were
required to show low pretest probabilities for obstructive
sleep apnea, restless legs syndrome, narcolepsy and psy-
chiatric disorders by providing responses in the normal range
on the Berlin questionnaire (0 or 1 positive categories; Netzer
et al., 1999), Hamilton Depression Rating Scale (≤7; Ham-
ilton, 1960), as well as in a clinical interview with a sleep
medicine physician. Subjects who had been diagnosed with
insomnia or excessive sleepiness prior to becoming night-
shift workers were excluded. All subjects completed a
standardized sleep diary for 2 weeks prior to the laboratory
protocol, and were instructed to maintain their usual sleep–
wake schedule. Subjects reporting an average time in bed
(TIB) <5 h per 24-h period during this screening phase were
excluded from participating in the laboratory study. They
were required to be free from head injury, hearing problems,
alcohol or substance abuse; must have been non-smokers;
and must not have consumed more than 300 mg of caffeine,
on average, per day. Finally, they were required to be free
from all central nervous system (CNS)-acting medication, as
well as beta-adrenergic blocking agents and other drugs that
are known to affect circadian rhythms or sleep–wake
function. Drugs encountered and disqualified included
sertraline, tamoxifen, paroxetine, zolpidem, metroprolol, ate-
nolol, bupropion, alprazolam, venlafaxine, methylphenidate,
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gabapentin, tramadol, diazepam, triazolam, levocetirizine,
buspirone, citalopram, lisdexamfetamine and trazodone. An
exception was made for shift workers with insomnia symp-
toms who had taken melatonin or sleep-promoting agents
while working night-time shifts, but had subsequently discon-
tinued medication and had been free of these agents for at
least 2 weeks prior to the laboratory study.
Ninety-five night workers initially responded to flyers and
online newsletter advertisements. Of these, 35 (36.8%) were
disqualified based on an online survey; 13 (13.7%) did not
comply with pre-screening requests to keep a sleep diary or
failed to keep a screening appointment; five (5.3%) were
disqualified at the screening appointment; three (3.2%) were
eligible but not enrolled; and one (1.1%) dropped out
following enrollment. Thirty-eight participants (40.0%) quali-
fied based on inclusion criteria. Of these 38 participants, 24
(63.2%) were randomly selected to participate in a genetic
sub-study, the results of which are reported here. Occupa-
tions of participants varied, and included a night inventory
stocker, nurses (93), a night-time pharmacist, various med-
ical/laboratory technologists (914), security guards (92), a
police officer, a radiographer and a respiratory therapist.
Participants were studied in both the summer and winter
months. The local Institutional Review Board approved all
study procedures, and written informed consent was
obtained from subjects prior to participation.
Participating subjects deposited 2 mL of saliva into an
Oragene OG-500 collection kit (DNA Genotek; Ontario,
Canada). Genomic DNA was extracted and genotyped for
on the PER3 VNTR. This VNTR has two alleles: a four-repeat
(short) allele; and a five-repeat (long) allele. Preparation and
analysis of the samples was performed by the Applied
Genomics Technology Center at Wayne State University
(Detroit, MI, USA).
The laboratory visit was scheduled to occur immediately
following at least two consecutive night-shifts. Participants
kept their normal sleep–wake schedules prior to the labora-
tory visit, including daytime sleep on the day of the study
(Table 1). Laboratory procedures were conducted in an
isolation facility with low light exposure (<15 lux) for the
duration of the protocol. Participants arrived at 16:00 hours
and, beginning at 17:00 hours on the day of the laboratory
study, saliva samples for melatonin processing were col-
lected at 30-min intervals using a Salivette tube with a cotton
insert (Sarstedt Group, Numbrecht, Germany). Prior to
17:00 hours, participants were instructed on the procedure
of saliva collection and the amount of saliva required for each
sample. Each sample was weighed to ensure that at least
1 mL of saliva was provided. Saliva was then extracted from
the cotton insert in a frozen centrifuge, and samples were
frozen at 20 °C until being shipped over dry ice to
SolidPhase (Portland, ME, USA), where they were radio-
immunoassayed. The intra-assay precision was 2.6–20.1%
with functional sensitivity of 0.9 pg mL1 and analytical
sensitivity of 0.2 pg mL1. With the exception of the research
multiple sleep latency test (MSLT), participants were not
permitted to sleep during the protocol, were required to
remain out of bed, and were observed by a technician/
research assistant throughout. Participants could ambulate
throughout the bedroom and a private bathroom and hallway
(all <15 lux). Telephone, television and internet usage were
permitted during unscheduled times, and three small meals
were provided to participants during the course of the
protocol. Caffeine, alcohol, milk, bananas and tomatoes
were not permitted. Participants were aware of clock time and
meals were provided on request. Meals were also supple-
mented with snacks upon request.
Dim-light melatonin onset (DLMO) is an individual’s char-
acteristic point in clock time marking the onset of elevated
melatonin levels that normally coincide with the sleep period
(Lewy and Sack, 1989; Revell et al., 2005). DLMO was
calculated as the time that the amplitude of the fitted
LOWESS curve for melatonin concentration rose and
remained above a participant’s melatonin threshold for at
least 1 h. The threshold used was the average of the five
lowest concentrations of melatonin during the 24-h phase
Table 1 Demographics and reported habitual sleep by genotype
4/4 –/5 P
% Female 72.7 76.9 0.82
% Asian 18.2 0 0.12
% African–American 54.5 84.6 0.12
Age (years) 36.27  9.83 33.85  8.77 0.53
Total sleep time (h) 5.74  1.02 5.51  1.14 0.61
Bed time (hours) 9:06  0.97 9:54  1.69 0.12
Wake up time (hours) 15:22  1.40 15:59  2.47 0.46
Sleep efficiency (%) 0.91  0.12 0.90  0.09 0.77
Sleep latency (min) 24.48  26.06 16.77  12.04 0.35
Wake after sleep onset (min) 6.46  12.63 11.79  19.52 0.45
Naps during shift (no. per week) 1.2  1.9 2.5  2.6 0.19
n 11 13
Sleep data were obtained using a standardized sleep diary. Bed times and wake times are calculated for days when subjects worked the
night-shift.
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assessment, plus 15% of the average of the five highest
concentrations. DLMOoff was calculated as the time at which
the LOWESS curve amplitude fell and remained below the
individual’s threshold for at least 2 h (Gumenyuk et al., 2012,
2014; Lee et al., 2006).
Objective sleepiness was assessed using a nocturnal and
diurnal MSLT. Eight naps were conducted at 2-h intervals
from 22:30 to 12:30 hours, following standard research
protocol. Thus, participants were awakened following three
epochs of stage 1 or one epoch of any other sleep stage.
Electrode integrity was checked by physical inspection and
electrical biocalibration before each nap. The first four naps
(22:30–04:30 hours) coincided with night-shift hours, while
the last four (06:30–12:30 hours) evaluated the effects of
acute sleep deprivation. Subjective sleepiness was assessed
by the Epworth Sleepiness Scale at 17:00 hours, which was
well over 1 h after arrival at the sleep laboratory to avoid
possible sleep inertia effects. The Stanford Sleepiness Scale
(SSS) was used to assess the dynamics of sleepiness
throughout the study for each participant, and was adminis-
tered immediately prior to each of the eight MSLT naps.
To assess the association between the VNTR genotype
and sleep phenotypes, a dominant genetic analysis model
was used, with individuals heterozygous (PER34/5) and
homozygous (PER35/5) for the long allele considered
together (PER3–/5) for comparison with individuals homozy-
gous for the short allele (PER34/4). This model was selected
due to the low frequency of PER35/5 homozygotes in the
sample (1 of 13; see Results). Association tests were
conducted using independent samples t-tests for continuous
variables and Pearson chi-square tests for categorical sleep
phenotypes. Where appropriate, ordinary least-squares
regression models were used to clarify the differential
contributions of genotype to sleepiness and circadian phase.
P-values <0.05 were considered statistically significant. All
data analyses were performed using SPSS Version 18.0 for
Windows (IBM, Armonk, NY, USA).
RESULTS
Of 24 shift workers in our sample, 13 (54.2%) were
homozygous or heterozygous carriers of the long VNTR
(PER3–/5); 12 of these 13 carriers (92.3%) were heterozy-
gous (PER34/5). The remaining 11 shift workers were
homozygous for the short allele (PER34/4). There were no
significant differences by carrier status for sex, age, race or
reported sleep parameters on work days (Table 1).
PER3–/5 shift workers had significantly lower MSLT latency
during overnight work hours. Averaged over four naps
from 22:30 to 04:30 hours, the mean MSLT score for
long-allele carriers was 3.52  3.44 min, compared with
10.39  6.41 min among short-allele homozygotes (P =
0.003). For naps between 06:30 and 12:30 hours (i.e. times
corresponding to acute sleep deprivation outside of the
circadian nadir), no significant difference (P = 0.249) was
observed between carriers of the long-allele (2.17  2.15)
and homozygotes for the short-allele (3.16  1.94). MSLT
scores for all eight naps are presented in Fig. 1. Sleepiness
reports on the SSS administered before each nap did not
differ between genotypes during night-shift hours (PER3–/5 =
2.95  0.81 and PER34/4 = 2.65  1.12, P = 0.456) or in
the morning (PER3–/5 = 3.33  1.13 and PER34/4 = 3.58 
1.72, P = 0.683). Despite the absence of observed differ-
ences on the SSS, long-allele carriers indicated significantly
higher sleepiness on the Epworth Sleepiness Scale
administered at 17:00 hours: PER3–/5 = 12.08  2.55 and
PER34/4 = 8.00  1.94 (P < .001).
As shift work constitutes a challenge to the circadian
system, we must be careful in interpreting the observed
sleepiness differences between genotypes. Other studies
refer to the enhanced overnight sleepiness differences in
PER35/5 individuals as occurring at the circadian nadir, but it
is reasonable to assume that many of the night-shift workers
have a circadian phase different from those of typical day
workers. Indeed, the mean DLMO time for our sample of shift
workers is 23:30  6:34 hours, which is later than that
typically reported for the day-working population (Burgess
and Fogg, 2008). Testing for genotype differences in circa-
dian phase, we found a significantly earlier DLMO
(P = 0.021) in PER3–/5 individuals (20:44  6:37 hours)
compared with PER34/4 shift workers (02:46  4:58 hours),
as well as significantly earlier DLMOoff times (P = 0.009) for
PER3–/5 individuals (07:58  6:19 hours) compared with
PER34/4 (14:41  4:51 hours) shift workers. Fig. 2 presents
the distribution of DLMO times within the two groups. The
duration of melatonin secretion (i.e. time between DLMO and
DLMOoff) was not significantly different between the geno-
type groups (11:12  1:09 h in PER3–/5 individuals versus
11:49  1:09 h in PER34/4, P = 0.224).
To differentiate between the genotype differences in
sleepiness and circadian phase, two linear regression mod-
els were estimated (Table 2). The first models the relation-
ship between overnight MSLT score and PER3 genotype,
adjusting for DLMO. Results from this analysis indicate that
Figure 1. MSLT latencies to sleep by PER3 genotype.
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PER3 genotype significantly predicts sleepiness even after
controlling for variations in circadian phase. The second
models the relationship between circadian phase and geno-
type, while adjusting for MSLT-assessed nocturnal sleepi-
ness. Results suggest that PER3 is not associated with
circadian phase when controlling for the MSLT.
DISCUSSION
The present study provides evidence that shift worker
carriers of the five-repeat allele of the PER3 VNTR have
significantly higher levels of sleepiness during overnight work
hours as well as significantly earlier (i.e. less adapted)
circadian phases. These results support the possibility that
the PER3 genotype is an important factor in the process of
physiological adjustment to the sleep–wake schedule asso-
ciated with night-shift work, and therefore carries important
clinical implications. The PER3 effects on both physiological
(MSLT) and self-report (ESS) measures of sleepiness are
robust and similar in magnitude (~5 min) to those found with
the use of wake-promoting agents to treat patients with shift
work disorder (Czeisler et al., 2009). Clinically, the ESS
mean for PER34/4 participants fell in the normal range, while
the mean for PER3–/5 patients was in the pathological range.
Although the groups did not differ on the SSS, this may be
related to the relative insensitivity of the SSS as a between-
groups measure compared with the ESS.
Genotype differences in circadian phase were also pres-
ent. Although these differences did not persist in a linear
regression model co-varying for sleepiness, the direction of
these differences (with PER34/4 workers being more likely to
show delayed phases) suggests that PER3–/5 workers are at
a severe disadvantage when it comes to shift work adapta-
tion: they suffer from increased sleepiness as well as
maladaptive circadian phase. This result is consistent with
a study demonstrating more rigid circadian control in PER35/5
homozygotes relative to other PER3 VNTR genotypes
(Archer et al., 2008).
A recent model of the effects of the PER3 VNTR on sleep
and wakefulness emphasizes the interrelatedness of circa-
dian rhythmicity and sleep homeostasis (Dijk and Archer,
2010). However, we must also consider the possibility that
PER3 may not directly influence both sleepiness and
circadian phase. While this sample was too small to perform
a mediation analysis, existing literature suggests a few
possibilities that may account for a possible causal pathway.
Our finding of an independent effect of PER3 on sleepiness,
but not on circadian phase, suggests that sleepiness may
moderate the relationship between genotype and circadian
phase. Dijk and Archer have proposed that a reduced build
up of homeostatic pressure associated with the PER3 four-
repeat genotype may prolong the onset of sleep, potentially
leading to differences in circadian phase (Dijk and Archer,
2010). Thus, elevated homeostatic sleep pressure in
excessively sleepy PER3–/5 shift workers in the present
study may have led these individuals to choose an earlier
bedtime, which may inhibit a physiological phase delay. On
sleep diaries and actigraphy, we did observe later
bedtimes on days off in PER4/4 workers, although these
differences did not reach statistical significance
(diary: PER3–/5 = 23:17  3:08 hours versus PER34/4 =
24:33  2:48 hours, P = 0.328; actigraphy: PER3–/5 =
22:25  3:13 hours versus PER34/4 = 24:12  2:25 hours,
P = 0.163). The present findings are also consistent with a
recent study showing that PER3 genotype may interact
with sleepiness to affect a worker’s chosen sleep strategy
(i.e. sleep deprivation) on a shift work schedule and
therefore indirectly influence circadian phase (Gamble
et al., 2011).
On top of these potential indirect influences of PER3 on
circadian phase, there is additional evidence suggesting a
direct effect. The five-repeat allele is associated with
increased sensitivity to light, resulting in increased sup-
pression of endogenous melatonin (Chellappa et al., 2012).
Due to the well-established phase–response curve of
Figure 2. Distribution of dim-light melatonin onset (DLMO) by
genotype.
Table 2 Ordinary least-squares regression models
B SE b
Model 1. Dependent variable: nocturnal sleepiness (MSLT
22:30–04:30 hours)
Constant 0.248 3.304
PER3 polymorphism 4.769* 1.925 0.482
DLMO 0.170 0.149 0.221
R2 0.381
Adjusted R2 0.322
Model 2. Dependent variable: circadian phase (DLMO)
Constant 0.543 1.866
PER3 polymorphism 0.086 1.087 0.019
Nocturnal MSLT 0.086 0.084 0.243
R2 0.064
Adjusted R2 0.026
DLMO, dim-light melatonin onset; MSLT, multiple sleep latency
test.
*P < 0.05.
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circadian rhythms to light (Minors et al., 1991), early
morning light exposure has been found to prevent circadian
adjustment (i.e. phase delay) to a simulated shift work
schedule (Smith et al., 2009). Thus, PER3–/5 individuals
(who are putatively more sensitive to light) may experience
a larger inhibition to adaptive phase delay from this early
morning ‘light brake’. Although differences in morning light
exposure are associated with differential circadian adjust-
ment in night workers (Gumenyuk et al., 2012), future
research is needed to determine if this effect differs
between PER3 genotypes.
It is well known that regular night work increases the risk
for a variety of cardiovascular (Akerstedt and Knutsson,
1997; Czeisler et al., 2009; Gamble et al., 2011; Leclerc,
2010; Murata et al., 1999; Puttonen et al., 2009) and
gastrointestinal (Vener et al., 1989) disorders, as well as
breast (Davis et al., 2001; Kamdar et al., 2013; Pijpe et al.,
2014; Wang et al., 2013) and prostate (Conlon et al., 2007;
Erren et al., 2011) cancers. Thus, in addition to the differ-
ences in circadian phase and sleepiness found in the present
study, future investigations are needed to determine if night-
shift workers with different length polymorphisms in PER3
have differential long-term health outcomes in response to
working night-shifts. The differences in circadian phase found
in these night workers who have been working the shift for
several years (mean time on night-shift in the present
sample: 4.34  3.58 years) suggest this should be a focus
of future investigations.
The present results may also have important implications
for occupational health. Considering the healthcare industry
alone, a litany of evidence indicates that medical and nursing
errors increase when health professionals are sleep
deprived. Over the past decade, mounting evidence has
linked the five-repeat allele of PER3 to accelerated homeo-
static dissipation, increased sleepiness at the circadian nadir,
and impaired cognitive performance compared with homo-
zygotes for the four-repeat allele. The present results are the
first to provide evidence of critical genotype differences
affecting objective sleepiness in night workers. A number of
ethical questions arise from this finding, including how to
handle differential genetic resistance to sleep loss in high-
stakes work or educational settings (e.g. graduate medical
education; Czeisler 2009). This is an area demanding critical
input from sleep scientists, occupational health researchers,
policymakers and medical ethicists.
While we believe this study provides compelling evi-
dence that genotypic differences in the PER3 VNTR confer
objective and clinically relevant differences in night work-
ers, several limitations should be noted. First, due to
sample size, we collapsed homozygotes and heterozygotes
for the five-repeat allele. Future research will be needed to
determine if homozygous PER35/5 night workers show
greater deficits in alertness and circadian adjustment than
PER34/5 heterozygotes. Second, circadian phase was only
assessed once (after several consecutive night-shifts).
Because there may be some variability in circadian phase
(especially among shift workers), future studies may benefit
from assessing circadian phase after consecutive night-
shifts as well as after consecutive days off from work. The
lack of differences in the MSLT following the sleep-
deprivation phase of the protocol was likely due to a floor
effect on the MSLT. Future studies examining sleep
deprivation effects related to genotype may benefit from
use of an alternative metric, such as the Maintenance of
Wakefulness Test, which is less likely to be influenced by
floor effects following prolonged sleep deprivation. Addi-
tional PER35/5 individuals may have increased the effect
sizes observed and should be specifically targeted for
recruitment in future trials. Lack of information regarding
light history of participants is also a limitation. Finally, our
sample was predominately female and African–American,
and we were not able to match subjects for age, ethnicity,
race or gender.
CONCLUSION
PER3–/5 night workers show significantly elevated levels of
sleepiness during night-shift hours on both the MSLT and
the ESS. In both cases, PER3–/5 shift workers showed
sleepiness in the pathological range, while their PER34/4
counterparts showed sleepiness within normal limits.
PER3–/5 night workers also show a mean circadian phase
6 h earlier (i.e. less adapted) than PER34/4 workers.
Regression modelling indicates that the five-repeat allele
is significantly associated with sleepiness, independent of
circadian phase, while the allele does not appear to exert
an independent effect on circadian phase net of its effect
on sleepiness. We interpret these findings as a call for
future research on the role of PER3 in determining
differential resilience to the challenges associated with
night work, raising a number of practical and ethical
questions for our 24-h society.
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